Abstract: Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CD5) involve two chimeric antigen receptors (CARs) specific to CD33 and CD5 and T cells with CD33 and CD5 dual-CAR. Methods of administering a genetically modified T cell expressing the dual-CAR can be used for autologous and allogeneic treatment of T cell malignancies.

Abstract: Provided herein are compositions for treating or preventing Retinitis Pigmentosa. The compositions comprise a first polynucleotide and a second polynucleotide. The compositions may further comprise a third sequence and a fourth sequence. Also provided herein are the recombinant adeno-associated virus particles, systems, methods, and kits for practicing or using the same.

Abstract: The present disclosure relates to a pharmaceutical composition for the treatment of Leber congenital amaurosis, and a method for treating Leber congenital amaurosis using the pharmaceutical composition.

Abstract: The present invention relates to a system for treating eye diseases, and a method for treating eye diseases using the system.

Abstract: Provided are a universal chimeric antigen receptor (CAR) T cell and preparation method and application thereof. The binding of the cell HLA-A/HLA-B to the TCR is inhibited; the TCR gene expression is silenced; the invention man be used for allogeneic tumor treatment and does not cause GVHD and HVG reaction during allogeneic infusion, and thus improves the survival and antineoplastic effect of allogeneic CAR-T cells in the receptor.

Abstract: The present disclosure relates to an engineered immune cell and use thereof. The present disclosure provides an engineered immune cell comprising a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells of the present disclosure, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.

Abstract: The present disclosure relates to an engineered immune cell and use thereof. The present disclosure provides an engineered immune cell comprising a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells of the present disclosure, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.

Abstract: A method for inhibiting metastasis of cancer cells is provided. Inhibitors of heparan sulfate (HS) or hyaluronic acid (HA) are applied to a tumor or a surgical location after removal of the bulk of the tumor. The inhibitors enzymatically cleave surface HS or HA; genetically modify cancer cells to decrease HS or HA production or interfere with the signaling pathway between HS or HA and a MMP or syndecan.